|
The document is a laboratory report from 3M detailing the determination of the presence and concentration of Potassium Perfluorooctanesulfonate (PFOS) in the serum and liver of Sprague-Dawley rats exposed to PFOS via gavage, initiated on May 26, 1998.
|
2006 |
AR226-0560
|
rBjb6VrvnR9Qq1yrojdB04rxJ |
23 |
|
The document contains attachments to a letter to C. Auer dated May 18, 2000, discussing studies and information related to perfluorooctane sulfonate (PFOS) and N-ethyl perfluorooctanesulfonamide (N-EtFOSA) that are believed to be in 3M's possession and relevant to the FIFRA docket.
|
2000 |
AR226-0377
|
ym4MxRmKJbGK9jE37GvarM6qX |
2 |
|
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, including details on N-ethylperfluorooctane sulfonamidoethanol, N-methylperfluorooctanesulfonamidoethyl acrylate, and other perfluorinated compounds.
|
2000 |
AR226-0378
|
VJ0yvk4nDJ0gVj0LG84RwYjvo |
8 |
|
The document contains attachments to a letter to C. Auer dated May 25, 2000, summarizing various acute toxicity studies on PFOA and its derivatives conducted by different laboratories, including inhalation and oral toxicity studies in rats and irritation studies in rabbits.
|
2000 |
AR226-0417
|
5bQBE8VYXGLr6RXOvmzB7BGRJ |
7 |
|
3M is providing the EPA with supplemental information on perfluorooctanoic acid (PFOA) and perfluorooctane sulfonates (PFOS) related to environmental science and health effects, including studies on toxicity and environmental monitoring, as part of ongoing discussions about fluorochemistry.
|
2000 |
AR226-0416
|
238ZndX120xmEnm6Xv2ZOMbg |
28 |
|
The document contains a list of toxicology studies and mutagenicity tests conducted on perfluorooctanoic acid (PFOA) and its derivatives, primarily by 3M and various laboratories, detailing various assays and evaluations of their genotoxic effects.
|
2000 |
AR226-0428
|
4aE6RVzz2JY4VXN4DzpK6dLm1 |
19 |
|
The document reports on the analysis of FC-143 content in serum and liver samples from a 90-day subacute toxicity study in rhesus monkeys, indicating adverse effects at higher dosage levels compared to a previous rat study, with both male and female monkeys accumulating FC-143 similarly.
|
2000 |
AR226-0448
|
6bzZaRxd843v8jLVKYN2OBgng |
2 |
|
The document contains various toxicology and pharmacokinetic study reports related to perfluorooctanoic acid (PFOA) and its derivatives (T-6067, T-6068, T-6069) conducted by 3M and Riker Laboratories, focusing on their absorption, toxicity, and distribution in rabbits and rats.
|
2000 |
AR226-0453
|
6RvVNMLOxaBrVk7kgakDjzORE |
121 |
|
The document is a final report from 3M Environmental Laboratory detailing a single-dose dermal absorption/toxicity study of a t-butyl ammonium salt of perfluorooctanoate (PFOA) in rabbits, which found that liver and serum levels of total organic fluorine were below practical quantitation limits, indicating minimal absorption.
|
2000 |
AR226-0454
|
Oz0n1Z6jop1Y8N4QBmxxZ8wQw |
233 |
|
The document details toxicology studies on PFOA (T-2998CoC) conducted by Riker Laboratories, Inc. for 3M, including an oral rangefinder study in pregnant rats to establish dosing for subsequent teratology studies.
|
2000 |
AR226-0462
|
emBoxeKBByRV2Gk5EKdJ1ZRBm |
9 |
|
The document contains attachments to a letter discussing various toxicology studies and epidemiological investigations related to PFOA exposure among workers at the Chemolite plant and other facilities, highlighting health status, mortality, and serum levels in occupational cohorts.
|
2000 |
AR226-0469
|
EqNRZMRm2oQG7xx1G8pKamLMj |
9 |
|
The document discusses toxicology studies on PFOS, specifically detailing findings from teratology studies indicating severe maternal toxicity and reduced fetal body weights in treated groups, as reported in correspondence from E. Marshall Johnson to William C. McCormick, III.
|
2000 |
AR226-0529
|
nm21MgzoBkqVQeY3MBQvQO4Yz |
3 |
|
This document includes attachments to a letter dated May 25, 2000, discussing toxicology studies and information on PFOA, along with a letter from E. Marshall Johnson to William C. McCormick, III, regarding teratology studies on PFOS and ethyl FOSE, dated November 12, 1982.
|
2000 |
AR226-0531
|
dQm4ddOeBD5kewodnVRyqaLaR |
3 |
|
The EPA is requesting additional information from 3M regarding their submissions on perfluoroalkyl compounds, specifically clarifying the composition of FC-95 and the confidentiality status of certain perfluoroalkyl sulfonates, as well as the identity of a perfluoroalkyl alcohol tested in a rat teratology study.
|
2000 |
AR226-0543
|
wy4zZnYzxzJrK3zo6EBzYyo6 |
2 |
|
This document is a response from 3M to the EPA regarding additional information on their perfluoroalkyl submissions, specifically addressing the composition of the test material FC-95, primarily potassium perfluorooctane sulfonate, and toxicology studies involving a mixture of perfluoroalkyl alcohols.
|
2000 |
AR226-0544
|
LpY0py7MzGeyrrV4GkVrD2wvd |
1 |
|
3M submitted a white paper titled "Sulfonated Perfluorochemicals in the Environment: Sources, Dispersion, Fate and Effects" as a supplemental notice regarding sulfonate-based fluorochemicals to the EPA under TSCA 8(e).
|
2000 |
AR226-0545
|
O3N1nBGYBQjGy6JkoqLGErjaj |
1 |
|
This document is a notification from 3M to the EPA regarding the submission of final reports for two-generation rat reproduction studies on N-Ethyl Perfluorooctyl Sulfonamido Ethanol (N-EtFOSE) and Perfluorooctane Sulfonate (PFOS) under TSCA 8(e).
|
2000 |
AR226-0551
|
bBybmvD0Onkn8jzQRxdwgMx21 |
1 |
|
3M submitted a supplemental TSCA Section 8(e) notice to the EPA regarding N-Ethyl Perfluorooctyl Sulfonamido Ethanol (N-EtFOSE) and Perfluorooctane Sulfonate (PFOS), including an amended final report on a two-generation rat reproduction study that found no significant toxicological effects on pup survival or growth at the
|
2000 |
AR226-0555
|
BvoydrjMGx8n5jGRE8r39kG8o |
4 |
|
The document is a final report on a combined oral fertility, developmental, and perinatal/postnatal reproduction toxicity study of PFOS conducted in rats, detailing the study's methods, results, and conclusions.
|
2000 |
AR226-0554
|
5bRBOE4Zb3b2b9aQL0GxaDgbz |
247 |
|
This document is a final report on a cross-fostering study of PFOS conducted in rats, detailing the study's methods, results, and conclusions as part of the sponsor's study number T-6295.13.
|
2000 |
AR226-0553
|
7kbKJ0R1o9910vZdgpBR7mnE |
257 |
|
The document is a correspondence from DuPont Haskell Laboratory to the EPA, providing summaries of studies conducted on Ammonium Perfluorooctanoate and Perfluorononanoate.
|
2000 |
AR226-0573
|
DDNeEdj1Nj90oqgL0xBxEo2Oa |
1 |
|
3M is submitting completed "Use and Exposure Information Profiles" (UEIPs) for various perfluorooctane sulfonate-related compounds to the EPA, ensuring the accuracy of industrial hygiene and release information.
|
2000 |
AR226-0575
|
NzJvMX8j6V5n1dr6LBmwqZap |
3 |
|
This document is a correspondence from 3M to the EPA, detailing the company's voluntary efforts to provide information on perfluorooctane sulfonates (PFOS) and related compounds, including various health effects studies and environmental science data submitted in April and May 2000.
|
2000 |
AR226-0587
|
108b0kvvxk76e58V0RNV9Ln3j |
3 |
|
3M has submitted a detailed phase-out plan to the EPA for products based on perfluorooctanesulfonyl fluoride (POSF) and indicated that it will discontinue the manufacture of perfluorooctanoic acid (PFOA) as part of its commitment to responsible environmental management.
|
2000 |
AR226-0588
|
dQOmRyyoM7JvzjJV7xBj7Xgqe |
11 |
|
This letter from 3M responds to an EPA request for additional information on ongoing studies related to perfluorinated compounds, indicating that while some study protocols and plans were provided, others are still in development and not yet available.
|
2000 |
AR226-0593
|
88Obbz95vz28JYovjLrnzN1B |
2 |
|
3M submitted a "Use and Exposure Information Profile" for perfluorooctanoic acid and salts to the EPA, detailing their industrial hygiene program that includes qualitative and quantitative exposure assessments to manage employee exposure risks.
|
2000 |
AR226-0594
|
3Q1J3D4K1x4LENEwMxq4BwB0y |
2 |
|
3M is confirming meetings with the EPA to present its phase-out plan for POSF-based chemistries, including discussions on alternative chemistries to replace perfluorooctanyl products and the characterization of perfluorobutane sulfonyl fluoride-based chemistries.
|
2000 |
AR226-0597
|
wr22gjNNwDQBDD89joRprkQEQ |
2 |
|
The document provides a voluntary use and exposure information profile for Perfluorooctanoic Acid (PFOA) and its salts, produced by 3M Company, detailing production processes, site locations, and estimated distribution amounts.
|
2000 |
AR226-0595
|
b51mQaw4MEbO6YqaMLKxjv8Dk |
28 |
|
This document is a summary from DuPont to the EPA regarding the use of Ammonium Perfluorooctanoate (APFO) as a fluoropolymer reaction aid, emphasizing that DuPont does not manufacture APFO, that most of it is removed from products before sale, and that industrial hygiene data indicates worker exposure levels are significantly below the ACGIH TLV.
|
2000 |
AR226-0598
|
nNQ2ZZrvy0wEayDOkpLwoJ6QG |
2 |
|
3M submitted a detailed phase-out plan to the EPA for products based on perfluorooctanesulfonyl fluoride (POSF) and indicated that production of perfluorooctanoic acid (PFOA) would be addressed separately, following their announcement to discontinue these materials by the end of 2000.
|
2000 |
AR226-0600
|
yeaMy79rYGRkg5qjEO1jV5m6 |
11 |
|
DuPont's correspondence outlines their non-manufacture of PFOS and PFOA, their use of PFOA as a surfactant in fluoropolymer production, and their commitment to provide the EPA with toxicity testing and exposure information on these perfluorinated compounds by May 26, 2000.
|
2000 |
AR226-0604
|
ErKvV2XeGQzoRyeakLnQqbLx |
1 |
|
The document is an email from Charles Auer of the EPA to Gerald Kennedy of DuPont, discussing a request for an extension on the submission date for exposure information on ammonium PFOA, with a new proposed deadline of June 23, 2000, while also acknowledging the need for toxicity information on PFOS and PFOA by May 26, 2000.
|
2000 |
AR226-0605
|
YwK29g2798QDmoG5QV2KD3NK |
1 |
|
This is a letter from DuPont's Haskell Laboratory for Toxicology and Industrial Medicine, addressed to an EPA official, confirming the attendance of representatives from various companies at a meeting scheduled for July 7, 2000.
|
2000 |
AR226-0606
|
68k9Gn7NOGR9YBeayVbz4Qxo |
1 |
|
This document is a note from the EPA regarding 3M's response to missing reports related to ongoing environmental studies on perfluorooctanesulfonates (PFOS), confirming the status of various studies including biodegradation and phytotoxicity.
|
2000 |
AR226-0609
|
EqaJzrkDkd92pVk0RbQ8Jeb04 |
6 |
|
3M submitted a TSCA Section 8(e) report to the EPA indicating that new data shows the half-life of perfluorooctane sulfonate (PFOS) in human serum is approximately 270 days, significantly lower than previous estimates of 1000-1500 days, based on a study of retired workers.
|
2000 |
AR226-0610
|
M4BZ8Jzpd8Qn3b58Bonq1KRgk |
2 |
|
This interim report from 3M Company details a study on the serum half-lives of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in retired fluorochemical production employees, indicating that PFOS has a half-life significantly lower than previously estimated, while PFOA's half-life is approximately one year.
|
2000 |
AR226-0611
|
Rj06ynRXJYggErkpgydYpYEV |
9 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding N-Methyl Perfluorooctanesulfonamido Ethanol (N-MeFOSE), indicating that a 13-week dietary study in rats showed liver effects and reduced body weights at higher doses, while the low dose did not produce significant adverse effects.
|
2000 |
AR226-0614
|
zzYm4aLk8Gyn65G32zwr1DYv0 |
2 |
|
3M submitted a CD containing documents related to perfluorooctane sulfonates and related compounds to the EPA, including sanitized versions of previously confidential information, as part of ongoing discussions about fluorochemistry.
|
2000 |
AR226-0612
|
Dp1qGVqK3ymrqQxQDV9zpx1B |
45 |
|
This letter discusses 3M's withdrawal from the market of certain PFOS-related products and requests the inclusion of imaging material uses on a "critical use list" for continued production beyond 2000, while expressing a willingness to collaborate with the EPA on finding suitable replacements.
|
2000 |
AR226-0617
|
jV3D0eXyqzg0pxgDL20Mv3jp |
1 |
|
Dynax Corporation's letter to the EPA discusses the phase-out of 3M's AFFF agents containing PFOA and PFOS, expressing disagreement with 3M's request for an extension of the phase-out deadline and highlighting the availability of alternative fluorochemicals produced by other manufacturers that do not contain these harmful substances.
|
2000 |
AR226-0618
|
6wxe6nQr6ppD3VkEw4E44RBgo |
6 |
|
The document discusses the environmental and health concerns associated with Perfluorooctyl Sulfonate (PFOS), produced primarily by 3M Company, highlighting its persistence, bioaccumulation, and toxicity, as well as its widespread presence in the blood of the general US population and wildlife.
|
2000 |
AR226-0619
|
mp9ykYJbmVkVz8nE0a0D5VxZZ |
17 |
|
Unreadable document.
|
2000 |
AR226-0623
|
2jxq3e1QOLNDy8jwmLbYxm7Q6 |
1 |
|
The document is a report prepared by 3M detailing the sources, dispersion, fate, and effects of sulfonated perfluorochemicals in the environment, including analytical methods and ecological risk evaluations.
|
2000 |
AR226-0620
|
QgLmprDvdd8r82bkqDXdX5abv |
51 |
|
The document outlines the objectives of a meeting between the EPA and 3M regarding the management of perfluorinated compounds (PFCs), focusing on product stewardship, risk assessments, and future communications strategies related to PFOA and PFOS initiatives.
|
2000 |
AR226-0626
|
RJG5zMK8JmZ11Gn867b140Ybn |
11 |
|
The document from 3M Medical Department dated March 7, 2000, outlines various reproductive and toxicological studies on perfluorooctane sulfonate (PFOS), noting findings such as perinatal mortality effects predominantly on pups, decreased cholesterol levels at high serum concentrations, and the tolerability of a 0.15 mg/kg/d dose over six months.
|
2000 |
AR226-0625
|
YDK6kVbRa9511JYVNY14mV8Nk |
11 |
|
This is a facsimile transmission from Latham & Watkins dated April 27, 2000, intended for Charles Auer and Oscar Hernandez at the EPA, containing confidential information.
|
2000 |
AR226-0628
|
oDxrYb6DmoqxYVqvmgGL3yq7g |
3 |
|
The document is a letter from the EPA's Chemical Control Division requesting 3M Corporation's assistance in arranging a meeting with global fluorochemical manufacturers regarding recent developments on PFOS.
|
2000 |
AR226-0630
|
99xNK4R4kQ4ODOa3BedaaXMnV |
1 |
|
The document discusses the phaseout of PFOS (perfluorooctanesulfonic acid) and highlights an important development regarding its status as a persistent, bioaccumulative, and toxic chemical, with plans to engage the OECD Secretariat for further discussion.
|
2000 |
AR226-0629
|
MG77awBx3G0VB6Z4613q8Gedx |
6 |
|
Dainippon Ink & Chemicals, Inc. expresses its commitment to environmental responsibility and plans to phase out products containing PFOS, while seeking clarification from the EPA regarding potential regulations affecting their customers who export PFOS-containing products to the U.S.
|
2000 |
AR226-0631
|
K6V0KXvvwBV9baQk6E4Xn7NMN |
2 |
|
The document discusses the OECD's coordination efforts to conduct a screening level risk assessment on PFOS and its derivatives in light of 3M Corporation's decision to phase out production for most uses, aiming to inform member countries about the associated human and environmental hazards and evaluate potential substitutes.
|
2000 |
AR226-0632
|
rprBq2La55jQBeqNvbnXBq1eq |
2 |
|
The document is a correspondence from the EPA to 3M regarding the submission of test data on perfluorochemicals, specifically outlining the requirements for studies related to acute systemic toxicity, skin and eye irritation, and exposure information, while clarifying that previously submitted studies need not be resubmitted.
|
2000 |
AR226-0633
|
rBq7MvdYzbDNJB45GYwJV8QYv |
2 |
|
The document is a request from the EPA for information on perfluorinated chemicals, specifically focusing on PFOA and PFOS, including health effects, environmental studies, and exposure data, with deadlines for submission of the requested information.
|
2000 |
AR226-0634
|
82QO7mQw3zaoMdz76wZmdR5Vd |
2 |
|
The document is a request from the EPA for 3M to provide complete final reports and relevant information on PFOS and other perfluorinated compounds, including health and environmental studies, within specified deadlines.
|
2000 |
AR226-0635
|
qDJEGpO6B64D8YdarGDGVB8R |
2 |
|
The document is a follow-up email from Barbara Leczynski of the EPA to 3M regarding a meeting on PFOS, confirming an extension for 3M to submit information on PFOS and outlining expectations for interim reports and relevant data submissions.
|
2000 |
AR226-0636
|
2RzRvmq3rOzxOQZBNkyYQQ94p |
1 |
|
3M is coordinating a meeting with the EU Commission on May 24 to discuss PFOS and will provide additional information on PFOS mixtures, PFOA, and other derivatives in the coming weeks.
|
2000 |
AR226-0637
|
7R8LZ13GO3O2rNgYop0Bnda3B |
1 |
|
The document is a presentation by Charles M. Auer of the EPA discussing PFOS (perfluorooctane sulfonic acid), highlighting its widespread industrial use, persistence in the environment, bioaccumulation in humans and wildlife, and associated developmental toxicity observed in animal studies, with 3M Corporation identified as the sole U.S. manufacturer.
|
2000 |
AR226-0639
|
MJBQ3mKLNzr9gEmo6LVnzB3Xj |
3 |
|
3M announced it is phasing out the production of perfluorooctanyl chemistry, including certain Scotchgard products and fire-fighting foams, due to increasing scrutiny on persistent materials, despite existing evidence suggesting these compounds do not pose significant health or environmental risks.
|
2000 |
AR226-0641
|
EddOx6b4ONZO4Yk5NjVXLvwyg |
2 |
|
Dainippon Ink & Chemicals Inc. is requesting a meeting with the U.S. EPA on September 15, 2000, to discuss issues related to PFOS.
|
2000 |
AR226-0642
|
qmgeqdkmXvKw7eMoDX6wvLNBn |
1 |
|
The document is a letter from the EPA to Dainippon Ink & Chemicals, Inc. regarding their decision to phase out perfluorooctyl sulfonate (PFOS) for certain uses, while the EPA expresses its willingness to discuss critical uses and potential substitutes, emphasizing the environmental persistence and health risks associated with PFOS.
|
2000 |
AR226-0643
|
n9KyZm1oGZMrpOK5wxpqgo7Om |
2 |
|
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, indicating that one specific environmental study is claimed as confidential business information (CBI) while all other studies are non-CBI.
|
2000 |
AR226-0644
|
Rp1L2RN8Q4kOOkz3OZdDvpyOV |
11 |
|
This document is a final report on a 4-week range-finding dietary toxicity study of N-Methyl Perfluorooctanesulfonamido Ethanol (N-MeFOSE, T-6314) conducted on rats, prepared for 3M by Covance Laboratories.
|
2000 |
AR226-0616
|
yre7jgdp4dkOZyLwyR7Mzje1n |
374 |
|
The document reports on a study of the hydrolysis stability of N-methylperfluorooctanesulfonamido-ethyl acrylate (MeFOSEA), revealing that its degradation half-lives vary with pH and temperature, with longer half-lives observed at lower temperatures and higher pH levels.
|
1999 |
AR226-0380
|
85vLZzww4bYer4gbxoMKyO54Z |
70 |
|
3M submitted a TSCA Section 8(e) supplemental notice to the EPA detailing refined analyses of human sera samples that confirmed the presence of perfluorooctane sulfonate (PFOS) and detected additional perfluorinated sulfonates (PFSs) and perfluorinated carboxylic acids (PFCAs).
|
1999 |
AR226-0540
|
nmbBz1YGRx8VE9m9nLzQokBbz |
3 |
|
The document is a correspondence from Larry R. Zobel of 3M to the EPA, summarizing findings from rat teratology studies on 3M fluorochemicals, specifically noting that a mixture of perfluoroethanol derivatives caused significant fetal malformations, including cleft palates and skeletal abnormalities.
|
1999 |
AR226-0542
|
krZdQZrRVpywKBjNJBE8R8Z0 |
5 |
|
3M submitted a supplemental notice to the EPA detailing recent studies on the detection of perfluorooctanesulfonate (PFOS) in tissue samples from various animal species, highlighting initial screening data on PFOS distribution in biota using high-performance liquid chromatography-tandem mass spectrometry.
|
1999 |
AR226-0541
|
mbmE5QgXNkyGM9XannMam37oO |
4 |
|
3M is sending the EPA two papers on perfluorooctane sulfonate (PFOS) and organic fluorochemistry, along with a note about a forthcoming preliminary exposure assessment, to facilitate a discussion on these topics.
|
1999 |
AR226-0546
|
mpE1019KLOzMV426kvOn6aR2g |
1 |
|
3M submitted an overview paper to the EPA detailing the manufacture, use, distribution, and environmental release of sulfonyl-based fluorochemicals, including PFOS, along with a preliminary life-cycle assessment of exposure pathways and ongoing stewardship initiatives.
|
1999 |
AR226-0549
|
zzrwkye1pjjBzwV9VLQm7wrrn |
2 |
|
The document discusses the science of organic fluorochemistry, detailing 3M Company's history and experience in synthesizing organofluorine molecules using the Simons Electro-Chemical Fluorination process, which replaces hydrogen atoms in organic feedstocks with fluorine.
|
1999 |
AR226-0547
|
Yr5nxO96V88RxnV1wNx9e1NGk |
12 |
|
The document reports on a cross-fostering study of PFOS (perfluorooctanesulfonate) conducted by 3M, detailing the study's methodology, findings, and analysis conducted between 1998 and 2000, with a focus on the effects of PFOS on rat development.
|
1999 |
AR226-0556
|
K6XaOy9n17oyN2LnropM4NYzX |
9 |
|
3M's January 21, 1999 document summarizes the biological effects, health risks, and future research plans related to perfluorooctane sulfonate (PFOS), noting its presence in human serum samples at levels of tens of parts per billion.
|
1999 |
AR226-0548
|
446yGoD8BmJzBwd0D9Rq7Ng4Q |
135 |
|
This is a final report for Protocol 418-009 detailing a combined oral fertility, developmental, and perinatal/postnatal reproduction toxicity study of N-EtFOSE in rats, with the sponsor's study number 6316.5 and a report date of June 30, 1999.
|
1999 |
AR226-0552
|
vV56RrRwZYRJB93mJrbe47gkw |
243 |
|
This document is a report prepared by 3M Company on May 26, 1999, providing an overview of the use, distribution, and environmental release of sulfonyl-based fluorochemicals, intended to inform exposure assessment and product stewardship initiatives.
|
1999 |
AR226-0550
|
Z4yEEd03Ybwm1OND67eKJVQeJ |
350 |
|
This document outlines a protocol for a pharmacokinetic recovery study of potassium perfluorooctane sulfonate (PFOS) in rats, conducted by 3M Environmental Technology and Safety Services, aimed at determining PFOS levels in liver and serum specimens.
|
1999 |
AR226-0566
|
3JbeL9nyQD7M0da8rVwGwVzj3 |
25 |
|
This document outlines the protocol for a pharmacokinetic study of potassium perfluorooctane sulfonate (PFOS) in rats, sponsored by 3M, aimed at determining PFOS levels in liver and serum specimens.
|
1999 |
AR226-0567
|
M422NndanGZpMEBkOX3NeOxvx |
24 |
|
The document is a final report detailing a pharmacokinetic study of PFOS conducted in rats, sponsored under study number T-6295.12, which includes methods, results, and conclusions regarding the absorption and distribution of PFOS in the test subjects.
|
1999 |
AR226-0565
|
2Nj66eMB2RVLLz26LbOaXVmq7 |
172 |
|
The document summarizes a two-generation reproduction study on PFOS (Perfluorooctanesulfonate) conducted on rats, detailing the dosing procedures, study design, and indicating that no deaths occurred in the parental generation (Fo) animals.
|
1999 |
AR226-0569
|
Mk6dXR0r47Z7EX9o7BrdDYb7 |
11 |
|
This document is the final report of a pharmacokinetic recovery study of PFOS conducted in rats, detailing the study's methods, results, and conclusions, with a focus on the absorption and elimination of PFOS in the test subjects.
|
1999 |
AR226-0568
|
rpmwKraoqvjrZgNw0qg88nmd7 |
160 |
|
The document is an analytical laboratory report detailing the determination of the presence and concentration of Perfluorooctanesulfonate (PFOS) in the serum of Sprague-Dawley rats that were exposed to potassium perfluorooctanesulfonate via gavage, conducted by 3M Environmental Laboratory.
|
1999 |
AR226-0570
|
8oOmLjkv0xop864w46Kgw8J5 |
113 |
|
This document is a final report on a combined oral fertility, developmental, and perinatal/postnatal reproduction toxicity study of PFOS conducted in rats, detailing the study's methods, results, and conclusions.
|
1999 |
AR226-0563
|
mrL6eXd48XZ6oDLoqmpm2KdB |
645 |
|
The document is a pathology report detailing an ancillary study on the pharmacokinetics of PFOS in CRL:CDBR VAF/Plus rats, indicating that no significant ultrastructural differences were found in the liver and lung tissues between treated and control groups.
|
1999 |
AR226-0572
|
8qBzpVeEQ5e1Dwdn5m78VrEo |
74 |
|
This document is the final report of a cross-fostering study on PFOS conducted in rats, detailing the study's methods, results, and conclusions, with the sponsor's study number T-6295.13 and a final report date of July 23, 1999.
|
1999 |
AR226-0571
|
9JZjpaOeLjxoG4MajegrEVDRq |
257 |
|
The document is a letter from the EPA to Dr. William A. Weppner of 3M, discussing the development of a product stewardship Memorandum of Understanding (MOU) regarding perfluorooctane sulfonyl fluoride and indicating the need for further review of health effects and exposure assessments before concluding on the appropriateness of such an agreement.
|
1999 |
AR226-0640
|
X4QrM323Yjn0M6NZYrdZO69K |
20 |
|
The document outlines a protocol for a 26-week toxicity study of Ammonium Perfluorooctanoate (APFO) in cynomolgus monkeys, sponsored by the APME Ad-Hoc APFO Toxicology Working Group, to evaluate its effects on enzyme levels, hormones, and biochemical parameters.
|
1998 |
AR226-0452
|
q321o9VNy3NND6vGbzwDKjbMG |
18 |
|
The document discusses a review of teratology studies on FC 95 and FC 143, concluding that an eye lens defect previously reported in FC 95 was a sectioning artifact and that teratogenic effects have not been demonstrated at non-maternally toxic doses, with additional studies planned for both compounds.
|
1998 |
AR226-0468
|
mBg9Yz8ZYNkjd0JXJ0BNw4YDB |
3 |
|
The document discusses an epidemiologic study by Olsen et al. examining the relationship between serum PFOA levels and reproductive hormone changes in male production workers at 3M, finding no significant associations with estradiol or testosterone, although a confounded increase in estradiol was noted among those with the highest PFOA levels.
|
1998 |
AR226-0474
|
7r6aEMj2RBLMeZVyBQ8DYVEE |
10 |
|
The document is a final report from 3M Company detailing an epidemiologic investigation of plasma cholecystokinin and hepatic function in production workers exposed to perfluorooctanoic acid (PFOA), which found no positive association between serum PFOA levels and clinical hepatic toxicity.
|
1998 |
AR226-0477
|
pmvq54RXxkQKxLjx7yrpJ2kBk |
67 |
|
The document provides information on the chemical identification and production process of Perfluorooctanesulfonyl fluoride (POSF) by 3M Company, detailing the use of Simons Electro-Chemical Fluorination (ECF) to synthesize organofluorine molecules.
|
1998 |
AR226-0576
|
nVzNqDmxOpkm4g5Re7roj8g2 |
25 |
|
The document provides information on N-Methyl perfluorooctanesulfonamide (MeFOSA), including its chemical identification, production process by 3M Company using Simons Electro-Chemical Fluorination, and notes that significant production occurs that is non-isolated and non-reportable under TSCA.
|
1998 |
AR226-0581
|
n939vGm9gmodB93NOap4dNQV2 |
20 |
|
The document provides information on N-Ethylperfluorooctylsulfonamido ethanol (EtFOSE), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis, distribution, and technical contact information.
|
1998 |
AR226-0582
|
6VK1qVNONnDqVR6dpME27kZd |
24 |
|
The document provides information on N-ethyl perfluorooctanesulfonamido ethyl methacrylate (EtFOSEMA), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis and characteristics.
|
1998 |
AR226-0585
|
e5e2r9NvLyykVmgB7EK6nqn5e |
20 |
|
The document provides information about N-Methyl perfluorooctanesulfonamidoethyl acrylate (MeFOSEA), a chemical produced by 3M Company using the Simons Electro-Chemical Fluorination process, detailing its synthesis and distribution.
|
1998 |
AR226-0586
|
KQ7J0G7Jo8Qzyj3nQ1krEGro |
25 |
|
3M Chemicals requested a meeting with the EPA to discuss fluorochemicals, specifically addressing their assessment that current data do not indicate significant health risks from PFOS levels in human populations.
|
1998 |
AR226-0621
|
a1GXNxw7QGdnx2KqxZGQjxgja |
2 |
|
This letter from 3M outlines action items agreed upon with the EPA regarding the development of a product stewardship agreement and the provision of health effects information and exposure assessments related to perfluorooctane sulfonic acid (PFOS).
|
1998 |
AR226-0624
|
GKeyVX9VDgZOp01K2D4n2Q39N |
1 |
|
The document is a final report on an acute oral toxicity study of T-6669, a substance sponsored by 3M, conducted in accordance with OECD guidelines at Corning Hazleton Inc., with the study completed on January 10, 1997.
|
1997 |
AR226-0420
|
qk4DKpXBjvQQ5vwgrG21wv9GG |
35 |
|
The document is a final report on a 5-day oral toxicity study of the substance T-6669, sponsored by 3M, conducted on rats by Corning Hazleton, with quality assurance reviews confirming compliance with FDA and OECD regulations.
|
1997 |
AR226-0451
|
851D1bOvaOezLNBQNjMdKOdnK |
90 |
|
The document is a final report of a single-dose intravenous pharmacokinetic study of T-6564, sponsored by 3M, conducted by Corning Hazleton Inc. on rabbits, with a completion date of April 18, 1997.
|
1997 |
AR226-0460
|
d9OpO86OoyVZykwrxZq37rRG |
34 |
|
This is a final report from Corning Hazleton Inc. (Laboratory Project Identification: CHW 6329-185) detailing a 5-Daily Dose Dermal Absorption/Toxicity Study of T-6564 in rabbits, sponsored by 3M, with a completion date of April 28, 1997.
|
1997 |
AR226-0461
|
vBQzbowN72Z6zZbMyeVa138JY |
49 |
|
This document reports on a study assessing plasma cholecystokinin levels and hepatic enzyme responses in 3M employees exposed to perfluorooctanoic acid (PFOA), finding no significant clinical hepatic toxicity or modulation of hepatic responses to obesity and alcohol consumption at observed PFOA levels.
|
1997 |
AR226-0476
|
zd4gkGOeq4pnrKnobq0mwdqg6 |
25 |
|
The document reports on a biodegradation study of perfluorooctylsulfonate, a fluorochemical produced by 3M, indicating that some portion of the test sample biodegraded in aerobic environments, although it could not rule out the potential for complete biodegradation under different conditions.
|
1997 |
AR226-0533
|
aBbX8Z33Zk3OyvnMDYx7rYNvb |
10 |
|
The document details an Activated Sludge Respiration Inhibition Test conducted on Perfluorooctylsulfonate (PFOS) produced by 3M, indicating that the test sample was a mixture of the substance in water and involved assessing its impact on activated sludge from a wastewater treatment plant.
|
1997 |
AR226-0539
|
gamDRpGDbjqnZpwDE5xpozBeV |
9 |